Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Demannose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL30973585 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL3397670 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL361547 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL31755099 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL23721809 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL25380809 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL6533561 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL25381696 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Galactose SCHEMBL361095 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL30572907 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050042705-A1 | Methods for the identification of inhibitors of mannosyltransferase as antibiotics | ICORIA, INC. | 2005-02-24 | — | — | US | claimed |
| WO-2005012544-A2 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF MANNOSYLTRANSFERASE AND MANNOSYLTRANSFERASE COMPLEX SUBUNIT AS ANTIBIOTICS | PARADIGM GENETICS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| CN-117701522-A | Alpha-1, 3-fucosyltransferase mutant and application thereof | 中国科学院上海高等研究院 | 2024-03-15 | — | — | CN | disclosed |
| EP-4291249-A2 | TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) | RegenxBio Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4096631-A1 | TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS | RegenxBio Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-110592214-B | Use of PGM2L1 gene in preparation of marker for diagnosing ovarian cancer, diagnostic reagent and therapeutic drug | 上海市东方医院（同济大学附属东方医院） | 2022-11-18 | — | — | CN | disclosed |
| EP-4087584-A2 | CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022173605-A2 | TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) | REGENXBIO INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4041219-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | Applied Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-3980085-A1 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | Ramot at Tel-Aviv University Ltd. (IL) | 2022-04-13 | — | — | EP | disclosed |
| CN-105233277-B | The CNS of therapeutic reagent is delivered | 夏尔人类遗传性治疗公司 | 2019-01-01 | — | — | CN | disclosed |
| US-20050042705-A1 | Methods for the identification of inhibitors of mannosyltransferase as antibiotics | ICORIA, INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012544-A2 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF MANNOSYLTRANSFERASE AND MANNOSYLTRANSFERASE COMPLEX SUBUNIT AS ANTIBIOTICS | PARADIGM GENETICS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1115737-A4 | NOVEL INTERFERON STIMULATED AND REPRESSED GENES | CLEVELAND CLINIC FOUNDATION (US) | 2004-11-24 | — | — | EP | disclosed |
| CN-1345372-A | Transgenic plants and methods for mycotoxin resistance | SINGENTA PARTICIPATION AG (CH) | 2002-04-17 | — | — | CN | disclosed |
| EP-1149163-A2 | HUMAN SERUM ALBUMIN | Delta Biotechnology Limited (GB) | 2001-10-31 | — | — | EP | disclosed |
| EP-1115737-A2 | NOVEL INTERFERON STIMULATED AND REPRESSED GENES | THE CLEVELAND CLINIC FOUNDATION (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000044772-A2 | HUMAN SERUM ALBUMIN | DELTA BIOTECHNOLOGY LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000022093-A2 | NOVEL INTERFERON STIMULATED AND REPRESSED GENES | CLEVELAND CLINIC FOUNDATION (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000020568-A1 | SUGAR TRANSFERASES OF PATHOGENS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-04-13 | — | — | WO | disclosed |